Serum biological antioxidant potential predicts the prognosis of hemodialysis patients

Nephron - Clinical Practice

Volumn 117, Issue 3, 2011, Pages

  Ishii, Tomoko ^a,b   Ohtake, Takayasu ^a   Okamoto, Koji ^b   Mochida, Yasuhiro ^a   Ishioka, Kunihiro ^a   Oka, MacHiko ^a   Maesato, Kyoko ^a   Ikee, Ryota ^a   Moriya, Hidekazu ^a   Hidaka, Sumi ^a   Doi, Kent ^b   Noiri, Eisei ^b   Fujita, Toshiro ^b   Kobayashi, Shuzo ^a  

^a SHONAN KAMAKURA GENERAL HOSPITAL   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Angiotensin converting enzyme inhibitors angiotensin II receptor blockers; Antioxidant; Biological antioxidant potential BAP; Hemodialysis patients

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIOXIDANT; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; UBIDECARENONE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DEATH; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HOSPITAL CHARGE; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; ANTIOXIDANTS; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY DISEASES; LIPID PEROXIDATION; MALE; MIDDLE AGED; OXIDATIVE STRESS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RENAL DIALYSIS; SURVIVAL RATE;

EID: 77956071094     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320201     Document Type: Article

References (23)

1. Vaziri ND: Oxidative stress in uremia: nature, mechanisms, and potential consequences. Semin Nephrol 2004;24:469-473. (Pubitemid 39361056)
2. Morena M, Delbosc S, Dupuy AM, Canaud B, Cristol JP: Overproduction of reactive oxygen species in end-stage renal disease patients: a potential component of hemodialysisassociated inflammation. Hemodial Int 2005;9:37-46. (Pubitemid 40932774)
3. Ward RA, McLeish KR: Oxidant stress in hemodialysis patients: what are the determining factors? Artif Organs 2003;27:230-236. (Pubitemid 36423478)
4. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002;62:1524-1538. (Pubitemid 35286260)
5. Lahera V, Goicoechea M, de Vinuesa SG, Oubina P, Cachofeiro V, Gomez-Campdera F, Amann R, Luno J: Oxidative stress in uremia: the role of anemia correction. J Am Soc Nephrol 2006;17: S174-S177. (Pubitemid 44865245)
6. Himmelfarb J, Hakim RM: Oxidative stress in uremia. Curr Opin Nephrol Hypertens 2003;12:593-598. (Pubitemid 38186749)
7. Ichikawa I, Kiyama S, Yoshioka T: Renal antioxidant enzymes: their regulation and function. Kidney Int 1994;45:1-9. (Pubitemid 24045986)
8. Dohi K, Satoh K, Ohtaki H, Shioda S, Miyake Y, Shindo M, Aruga T: Elevated plasma levels of bilirubin in patients with neurotrauma reflect its pathophysiological role in free radical scavenging. In Vivo 2005;19:855-860. (Pubitemid 41065144)
9. Perrone S, Longini M, Marzocchi B, Picardi A, Bellieni CV, Proietti F, Rodriguez A, Turrisi G, Buonocore G: Effects of lutein on oxidative stress in the term newborn: a pilot study. Neonatology 2009;97:36-40.
10. James AM, Smith RA, Murphy MP: Antioxidant and prooxidant properties of mitochondrial coenzyme Q. Arch Biochem Biophys 2004;423:47-56. (Pubitemid 38198212)
11. Arroyo A, Navarro F, Gomez-Diaz C, Crane FL, Alcain FJ, Navas P, Villalba JM: Interactions between ascorbyl free radical and coenzyme Q at the plasma membrane. J Bioenerg Biomembr 2000;32:199-210. (Pubitemid 30602307)
12. Constantinescu A, Maguire JJ, Packer L: Interactions between ubiquinones and vitamins in membranes and cells. Mol Aspects Med 1994;15(suppl): s57-s65.
13. Marcoff L, Thompson PD: The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007;49:2231-2237. (Pubitemid 46856819)
14. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M, Green MS: Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000;356:1213-1218.
15. Ando Y, Ito S, Uemura O, Kato T, Kimura G, Nakao T, Hattori M, Fukagawa M, Horio M, Mitarai T: CKD clinical practice guidebook. The essence of treatment for CKD patients. Clin Exp Nephrol 2009;13:191-248.
16. Nakayama K, Terawaki H, Nakayama M, Iwabuchi M, Sato T, Ito S: Reduction of serum antioxidative capacity during hemodialysis. Clin Exp Nephrol 2007;11:218-224. (Pubitemid 47476795)
17. Mosca F, Fattorini D, Bompadre S, Littarru GP: Assay of coenzyme Q (10) in plasma by a single dilution step. Anal Biochem 2002;305:49-54. (Pubitemid 34575824)
18. Sozzani S, Bosisio D, Mantovani A, Ghezzi P: Linking stress, oxidation and the chemokine system. Eur J Immunol 2005;35:3095-3098. (Pubitemid 41672513)
19. Pascual C, Karzai W, Meier-Hellmann A, Oberhoffer M, Horn A, Bredle D, Reinhart K: Total plasma antioxidant capacity is not always decreased in sepsis. Crit Care Med 1998;26:705-709. (Pubitemid 28201417)
20. Kakita H, Hussein MH, Daoud GA, Kato T, Murai H, Sugiura T, Mizuno K, Yamada Y, Ito T, Fukuda S, Kato I, Suzuki S, Togari H: Total hydroperoxide and biological antioxidant potentials in a neonatal sepsis model. Pediatr Res 2006;60:675-679. (Pubitemid 44789508)
21. Sakata T, Furuya R, Shimazu T, Odamaki M, Ohkawa S, Kumagai H: Coenzyme Q10 administration suppresses both oxidative and antioxidative markers in hemodialysis patients. Blood Purif 2008;26:371-378.
22. Napoli C, Sica V, de Nigris F, Pignalosa O, Condorelli M, Ignarro LJ, Liguori A: Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J 2004;148: e5.
23. Dohi Y, Ohashi M, Sugiyama M, Takase H, Sato K, Ueda R: Candesartan reduces oxidative stress and inflammation in patients with essential hypertension. Hypertens Res 2003;26:691-697. (Pubitemid 37258655)